The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place this week in Rwanda, a country of just over 14 million people that has become a continental leader in HIV ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

New data presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) yesterday show that two long-acting injectable PrEP options, lenacapavir and cabotegravir, are safe, well ...

A randomised trial presented on Tuesday at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight gain did ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented yesterday at the 13th International AIDS Society Conference ...

Intermittent HIV treatment schedules – such as weekends off treatment – may not be inferior to continuous treatment in adults with well-controlled HIV, but they are not suitable for adolescents with ...

Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment ...

HIV funding crisis the focus of IAS 2025 Professor Linda-Gail Bekker at IAS 2025. ©Jean Bizimana/IAS. CC BY-SA 4.0. The global HIV response confronts its most severe funding crisis in decades ...

As doxycycline post-exposure prophylaxis (doxyPEP) for prevention of sexually transmitted infections (STIs) enters widespread use, questions remain about its implementation in the real world. At a ...

Killer T-cells (CD8 cells or cytotoxic T-lymphocytes) engineered to mount a rare and specific reaction to HIV-infected cells that was first seen in an experimental vaccine more than a decade ago were ...

aidsmap is an award-winning, community-based organisation, which works from the UK. We deliver reliable and accurate HIV information across the world to HIV-positive people and to the professionals ...